Mission and Objectives

Mission

Our mission is to be a centre where collaboration and cooperation between biomedical and clinical research groups are prioritised and furthered, in which special emphasis is placed on aspects of genetic, molecular, biochemical and cell research of rare, genetic or acquired diseases.

The aim is to improve our knowledge on epidemiology, the causes and mechanisms for production of rare diseases. This research is the basis for providing new tools for diagnosis and therapy of rare diseases, backing translational or transfer research between the scientific medium of the laboratory and the clinical medium of healthcare centres.

Objectives

CIBERER has to be in line with the State Plan for Scientific, Technical and Innovative Research 2013-2016, and, on a higher level, with the new community programme Horizon 2020, and which as regards rare diseases follows the objectives marked by the International Rare Diseases Research Consortium (IRDiRC). The IRDiRC is an initiative promoted by the Council of Europe and the United States, to achieve 200 new therapeutic strategies, diagnostic innovations and a global database based on state registers, from now to 2020.

CIBERER aims to develop high quality cooperative and innovative research into Rare Diseases, fostering the transfer of results to clinical practice. The specific objectives are mainly based on the development of new treatments and improving access to diagnosis of RDs.

To face this challenge the CIBERER is working in close cooperation with all the agents involved in the field of RD nationally and internationally to:

  • Establish and provide access to data, standardised relevant information in RD.
  • Carry out molecular and clinical characterisation of RD.
  • Further translational, preclinical and clinical research into RD.
  • Rationalise the ethical procedures and rules in RD.

For these purposes the lines of action on which work has been done over these years of its existence will be maintained: networking, excellence research, collaborative and cooperative research, translation and transfer of results, as well as the social conspicuousness of RD. As a complement we will also continue to back the internationalisation of research, effective relations with the production sector and institutional visibility.